Breakthrough in pancreatic cancer: The drug that doubled survival

Significant news in the fight against one of the deadliest and hardest-to-treat cancers: a new oral drug has nearly doubled the median survival of patients with metastatic pancreatic cancer who had already received prior treatment, compared to standard chemotherapy.

The drug, Daraxonrasib (RMC-6236), was tested in a phase 3 study called RASolute 302. The study results showed that the median overall survival among patients who received the drug was 13.2 months, compared to 6.7 months among those who received chemotherapy. This is nearly double—a particularly significant figure for a disease where therapeutic progress has been limited for years and mortality rates remain high.

A target considered difficult to treat for years

One of the factors making this drug intriguing is its mechanism of action. Daraxonrasib is an oral drug that targets the RAS protein family, which are involved in processes that allow cancer cells to grow and multiply. Mutations that activate the RAS pathway are found in more than 90% of pancreatic ductal adenocarcinoma tumors. For years, RAS was considered one of the most difficult targets for drug development. Daraxonrasib is designed to inhibit several forms of RAS activity rather than focusing on just one specific mutation—an approach that may expand the number of patients eligible for treatment in the future.

Beyond survival: more patients responded to treatment

The response rate to treatment also showed a significant gap. According to the study, 33.2% of patients who received Daraxonrasib responded to treatment, compared to 11.8% among those who received chemotherapy. In addition, the drug significantly extended the duration of time patients lived without disease progression. The study included patients with metastatic pancreatic cancer who had already received a prior line of therapy based on 5-FU or gemcitabine. Therefore, at this stage, the findings indicate suitability for a defined patient population rather than every patient diagnosed with the disease.

A pill instead of chemotherapy

Another difference is the method of administration. Unlike chemotherapy, which is given by infusion, Daraxonrasib is taken orally once a day. The side effect profile was found to be manageable, with mainly rash, diarrhea, and nausea observed. Researchers noted that no new safety signals were identified, though continued monitoring will be necessary if the drug is approved for widespread use.

The ball is in the FDA's court

Following the study results, the developer, Revolution Medicines, submitted an application for approval. In early August, the company announced that the US Food and Drug Administration (FDA) had accepted the application for review, a significant step toward possible approval. However, it is important to emphasize that acceptance for review is not approval, and the drug is still defined as an experimental treatment.

If the data eventually leads to regulatory approval, it could be particularly significant for patients with a disease where options after the failure of the first line of therapy remain limited. The 13.2 months versus 6.7 figure does not guarantee that every patient will live twice as long, as it represents the median survival of the study groups. Nevertheless, for metastatic pancreatic cancer, where any significant progress is difficult to achieve, these results point to a promising new therapeutic direction.